Standard BioTools Inc.
NASDAQ:LABMedical - Devices
+$0.03 today
- Market cap
- $225.03M
- Beta
- 1.38
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.24
Volume 0.70M
Average 2.91M
LAB Total Debt
Short-term and long-term borrowings combined.
Standard BioTools Inc.NASDAQ: LAB
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 6.5% from a year ago
Total debt stood at $29.49M at the end of Q1 FY2026, down 6.5% from a year earlier and down 4.3% from the prior quarter. Over 3 fiscal years it compounded at -33.0% a year.
Context
- Total debt amounted to 4.6% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -6.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 30.83M USD
- Year-over-year change
- -6.6%
- 4-year CAGR
- -27.5%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.83M | -6.6% |
| FY2024 | 2024-12-31 | 33M | -66.4% |
| FY2023 | 2023-12-31 | 98.21M | -4.3% |
| FY2022 | 2022-12-31 | 102.66M | -8.1% |
| FY2021 | 2021-12-31 | 111.65M | — |
Total Debt vs competitors
How LAB compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -6.5% is the 7th highest of 11, against a peer median of -0.1%.
- Total debt amounts to 4.6% of total assets for LAB, versus a peer median of 13.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Apr 2026 | $381M USD | -36.2% | -2.7% | 35.0% | |
| Mar 2026 | CN¥379M CNY | +53.3% | +61.5% | 14.3% | |
| Mar 2026 | $272.08M USD | -21.3% | -9.4% | 41.8% | |
| Mar 2026 | $138.4M USD | -1.8% | -22.5% | 13.2% | |
| Mar 2026 | $116.67M USD | -74.1% | +50.1% | 40.0% | |
| Mar 2026 | $106.28M USD | +45.2% | +379.5% | 21.2% | |
| Mar 2026 | $36.33M USD | +128.5% | +9.5% | 8.1% | |
| Mar 2026 | $29.49M USD | -6.5% | -33.0% | 4.6% | |
CBLLCeriBell, Inc. | Mar 2026 | $22.12M USD | +1.6% | +6.9% | 12.4% |
| Mar 2026 | $13.55M USD | -80.5% | -41.1% | 7.4% | |
| Mar 2026 | $2.38M USD | +29.5% | -19.7% | 0.6% | |
| Peer median (excluding LAB) | — | -0.1% | +2.1% | 13.7% | |
Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.45M | 81.31M | 51.7M | 166.73M | 118.21M |
| Short-term Investments | 0 | 84.48M | 63.19M | 126.15M | 69.36M |
| Net Receivables | 18.32M | 17.28M | 19.66M | 33.61M | 13.43M |
| Inventory | 20.83M | 21.47M | 20.53M | 40.74M | 19.98M |
| Other Current Assets | 16K | 4.28M | 3.13M | 8.66M | 233.28M |
| Total Current Assets | 72.07M | 208.82M | 158.22M | 375.88M | 454.26M |
| Property, Plant & Equipment (Net) | 65.15M | 59.54M | 54.85M | 71.38M | 46.01M |
| Goodwill | 106.38M | 106.25M | 106.32M | 111.3M | 0 |
| Intangible Assets | 27.93M | 12.6M | 1.4M | 28.95M | 0 |
| Long-term Investments | 1M | 0 | 0 | 0 | 25.7M |
| Tax Assets | (1M) | 0 | 0 | 0 | 38.63M |
| Other Non-current Assets | 3.69M | 3.11M | 2.29M | 24.83M | 3.15M |
| Total Non-current Assets | 203.15M | 181.5M | 164.85M | 236.46M | 113.49M |
| Total Assets | 275.21M | 390.31M | 323.07M | 612.34M | 567.75M |
| Account Payables | 10.6M | 7.91M | 9.24M | 12.28M | 5.41M |
| Short-term Debt | 6.84M | 2.08M | 59.53M | 0 | 5.49M |
| Tax Payables | 1.41M | 1.17M | 825K | 1.58M | 0 |
| Deferred Revenue | 15.48M | 14.44M | 16.74M | 18.59M | 38.95M |
| Other Current Liabilities | 8.67M | 3.97M | 12.05M | 14.71M | 58.46M |
| Total Current Liabilities | 49.57M | 43.44M | 109.33M | 65.89M | 108.31M |
| Long-term Debt | 64.21M | 62.81M | 3.98M | 299K | 299K |
| Deferred Tax Liabilities | 4.33M | 1.06M | 841K | 1.08M | 810K |
| Deferred Revenue (Non-current) | 24.08M | 18.18M | 14.28M | 39.92M | 7.79M |
| Other Non-current Liabilities | 882K | 312.21M | 312.32M | 6.96M | 1.21M |
| Total Non-current Liabilities | 131.05M | 428.33M | 361.79M | 74.73M | 35.15M |
| Total Liabilities | 180.62M | 471.78M | 471.12M | 140.62M | 143.46M |
| Common Stock | 77K | 80K | 83K | 396K | 404K |
| Retained Earnings | (736M) | (926.1M) | (1B) | (1.19B) | (1.26B) |
| Accumulated OCI | (907K) | (1.9M) | (2.22M) | 1.23M | (1.49M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 94.6M | (81.47M) | (148.05M) | 471.72M | 424.29M |
| Total Debt | 111.65M | 102.66M | 98.21M | 33M | 30.83M |
| Net Debt | 83.2M | 21.35M | 46.51M | (133.73M) | (87.39M) |
Standard BioTools Inc.
NASDAQ:LAB
Intrinsic Alpha fair value
Locked
Current Price
$0.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.